CERo TherapeuticsCERO
About: CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
Employees: 8
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more capital invested
Capital invested by funds: $318K [Q3] → $956K (+$638K) [Q4]
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
18% more funds holding
Funds holding: 17 [Q3] → 20 (+3) [Q4]
0.31% more ownership
Funds ownership: 6.64% [Q3] → 6.95% (+0.31%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
D. Boral Capital Jason Kolbert 26% 1-year accuracy 96 / 365 met price target | 1,136%upside $11 | Buy Maintained | 25 Apr 2025 |
Financial journalist opinion
Based on 6 articles about CERO published over the past 30 days









